$VRDN News
Last published 5d ago
- 5d agoVRDNViridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous DosingBusiness WireWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced positive phase 1 results for VRDN-008. “Today's VRDN-008 data exceeded expectations and demonstrates a potentially transformative FcRn-inhibitor profile. Based ...
- 1w agoVRDNViridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026Business WireWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1 clinical trial in healthy volunteers and development plans for its neona ...
- 1w agoVRDNViridian Therapeutics Q3 2026 Earnings Call - VIRIDIAN THERAPEUTICS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the Viridian Therapeutics Conference Call. At this time, participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions w
- 1w agoVRDNViridian Therapeutics, Inc.\DE - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3w agoVRDNViridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it
- 3mo agoVRDNViridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial ResultsBusiness Wire- Lumvoa™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S. - - Elegrobart, potentially the first subcutaneous
- 4mo agoUPCDCOYVRDN4 Sizzling Biotech and Healthcare Companies Reporting Strategic MilestonesGlobeNewswireDENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives
- 4mo agoVRDNViridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye DiseaseBusiness Wire- First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED - - In two pivotal phase 3 clinical trials, Lumvoa treatment showed rapid, consistent, and
- 5mo agoVRDNViridian Therapeutics to Participate in Upcoming June Investor ConferencesBusiness WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that
- 6mo agoVRDNViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 MillionBusiness WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing
- 6mo agoVRDNViridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred StockBusiness WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced that it has
- 6mo agoVRDNREVEAL-2 Phase 3 Topline Results - VIRIDIAN THERAPEUTICS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the Viridian Therapeutics Conference Call to review top-line results from the REVEAL-2 Phase 3 Clinical Trial in Chronic Thyroid Eye Disease. At this time, participants
- 6mo agoVRDNViridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent ProgressBusiness Wire- PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease (TED); organization is launch-ready - - Marketing Authorization Application (MAA) for veligrotug in TED submitted to the European
- 6mo agoVRDNViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye DiseaseBusiness Wire- REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved 50% and 54% proptosis responder rates (PRR) at week 24, respectively, versus 15%
- 7mo agoVRDNViridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye DiseaseBusiness Wire- REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18%
- 8mo agoVRDNViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire- PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch - - Marketing Authorization Application (MAA) for
- 10mo agoVRDNViridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye DiseaseBusiness Wire- PDUFA target action date of June 30, 2026 - - Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement in the safety or effectiveness of treating a
- 11mo agoVRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the
- 1y agoVRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the
- 1y agoVRDNViridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent ProgressBusiness Wire- Completed a comprehensive set of financing transactions in October 2025, securing access to up to $889 million of potential capital across equity, royalty, and credit - - Successful October submission of Biologics
- 1y agoVRDNViridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye DiseaseBusiness Wire- BLA for veligrotug successfully submitted to the U.S. Food and Drug Administration (FDA) in late October following recent consultation with the agency - - Veligrotug's Breakthrough Therapy Designation supports
- 1y agoVRDNViridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common StockBusiness WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced the pricing of
- 1y agoVRDNViridian Therapeutics Announces Proposed Underwritten Public OfferingBusiness WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has
- 1y agoVRDNViridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 MillionBusiness Wire- Viridian receives $55 million upfront and potential near-term milestones up to $115 million based on positive VRDN-003 topline data and U.S. veligrotug marketing approval - - Upfront and anticipated near-term
- 1y agoVRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the
- 1y agoVRDNViridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio UpdatesBusiness Wire- Enrollment complete in VRDN-003's phase 3 clinical trials in thyroid eye disease (TED), REVEAL-1 and REVEAL-2, with each study exceeding its enrollment target due to strong patient demand; topline data on track for
- 1y agoVRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the
- 1y agoVRDNViridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial ResultsBusiness Wire- Robust execution with multiple upcoming near-term milestones, including planned Biologics License Application (BLA) submission for veligrotug on track in 2H 2025 and expected U.S. commercial launch in 2026 - -
- 1y agoVRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the
- 1y agoVRDNViridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone PaymentsBusiness Wire- Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan - - Viridian to receive an upfront payment of $70 million - - Additionally, Viridian is eligible to receive up to
- 1y agoVRDNViridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the
- 1y agoVRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the
- 1y agoVRDNViridian Therapeutics to Participate in Upcoming June Investor ConferencesBusiness WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that
- 1y agoVRDNViridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)Business Wire- 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week 52 - - Veligrotug recently received Breakthrough Therapy Designation (BTD), supporting
- 1y agoVRDNViridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)Business Wire- Breakthrough Therapy Designation request based on veligrotug's (i) consistent and robust improvement and resolution of diplopia in chronic TED, and (ii) rapid onset of proptosis response - - Veligrotug met all of its
- 1y agoVRDNViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial ResultsBusiness Wire- Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3
- 1y agoVRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the
- 1y agoVRDNViridian Therapeutics Appoints Jeff Ajer to its Board of DirectorsBusiness Wire- Mr. Ajer was most recently Chief Commercial Officer at BioMarin - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for
- 1y agoVRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that a
- 1y agoVRDNViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial ResultsBusiness Wire- Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the standard of care in TED
- 1y agoVRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the
- 1y agoVRDNViridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye DiseaseBusiness Wire- Veligrotug, with recent positive phase 3 topline data in both active and chronic thyroid eye disease (TED), has the potential to transform the standard of care in TED with a differentiated clinical profile achieved
- 1y agoVRDNViridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye DiseaseBusiness Wire- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2
- 1y agoVRDNViridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024Business Wire- THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET
- 1y agoVRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the
- 2y agoVRDNViridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn DataBusiness Wire- Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in December 2024 - - Initiated
- 2y agoVRDNViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireViridian Therapeutics, Inc. (NASDAQ:VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced
- 2y agoVRDNViridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred StockBusiness WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten
- 2y agoVRDNViridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred StockBusiness WireViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an
- 2y agoVRDNViridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye DiseaseBusiness Wire- Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder